Aengus Tran

Aengus Tran has spent the past decade working on a stubborn clinical problem: how to make specialist interpretation available when demand grows faster than the workforce. In 2025, the company he cofounded raised US$112 million to extend its radiology systems across new markets and modalities. The more consequential milestone arrived in March 2026, when Annalise Enterprise received a US 510(k) clearance for triage and worklist prioritization of suspected acute infarct on non-contrast brain CT in adults. The regulator's summary records a training set of more than 200,000 CT brain studies and makes the boundary equally clear: the software supports prioritization, does not replace advanced imaging and is not a rule-out device.

Tran's distinction lies in joining medical training, product accountability and international execution. He has built at the difficult seam between model performance and clinical workflow, where interoperability, quality systems and responsible labeling matter as much as an algorithm. The work is not evidence that artificial intelligence can diagnose independently. It is evidence that a young Asian-diaspora founder has moved a clinically consequential system through one of the world's most scrutinized device pathways while building an organization capable of operating across health systems.